Comparative Pharmacology
Head-to-head clinical analysis: BRANCHAMIN 4 versus CYSTADANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRANCHAMIN 4 versus CYSTADANE.
BRANCHAMIN 4% vs CYSTADANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential branched-chain amino acids (leucine, isoleucine, valine) to correct deficiencies and support protein synthesis in catabolic states; serves as a substrate for energy production and muscle metabolism.
Betaine acts as a methyl group donor in the remethylation of homocysteine to methionine, a reaction catalyzed by betaine-homocysteine methyltransferase. This reduces elevated homocysteine levels in homocystinuria.
1-1.5 g/kg/day intravenously, infused at a rate not exceeding 10 g/hour.
100 mg/kg/day orally divided into 3 doses, maximum 100 mg/kg/day; typical adult dose 6-9 g/day in divided doses.
None Documented
None Documented
Terminal elimination half-life of individual amino acids ranges from 0.5 to 2 hours; clinical context: rapid clearance requires continuous infusion to maintain plasma levels
Cystadane (betaine anhydrous) has a terminal elimination half-life of approximately 14 hours (range 10-18 hours) following oral administration, supporting twice-daily dosing. The half-life is prolonged in patients with renal impairment.
Primarily renal; >90% of infused amino acids are excreted in urine as metabolites (urea, ammonia) within 24 hours; minimal biliary/fecal elimination (<5%)
Renal excretion of unchanged betaine accounts for less than 5% of the administered dose; metabolism occurs via demethylation to dimethylglycine, which is further metabolized to sarcosine and glycine. Metabolites are excreted renally. A small fraction may be eliminated in feces.
Category C
Category C
Amino Acid Supplement
Amino Acid Supplement